Skip to Content

Agilent Technologies Inc A

Morningstar Rating
$142.86 +3.80 (2.73%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Agilent Earnings: Maintaining Our $151 Fair Value Estimate After Results Exceed Expectations

Wide-moat Agilent Technologies delivered fiscal first-quarter results that were better than management's targets. However, it merely maintained its outlook for fiscal 2024. Our view for 2024 remains slightly more optimistic on the top line and at the high end of the bottom line compared with management's target ranges. At first glance, we do not anticipate changing our $151 fair value estimate. The shares appear to be rising closer to our fair value estimate in after-hours trading on these strong quarterly results.

Price vs Fair Value

A is trading at a 5% discount.
Price
$142.86
Fair Value
$865.00
Uncertainty
Medium
1-Star Price
$179.31
5-Star Price
$975.30
Economic Moat
Wvcw
Capital Allocation
Jnbdbvtmp

Bulls Say, Bears Say

Bulls

Agilent's innovation engine and cost control efforts have been on display through strong growth and margin expansion since spinning out its electronic measurement business Keysight in November 2014.

Bears

Due to its dependence on one-time sales and its exposure to some cyclical end markets, Agilent's financial results may weaken during uncertain times.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if A is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$139.06
Day Range
$138.81143.49
52-Week Range
$96.80145.44
Bid/Ask
$136.40 / $144.97
Market Cap
$41.86 Bil
Volume/Avg
2.2 Mil / 1.7 Mil

Key Statistics

Price/Earnings (Normalized)
26.31
Price/Sales
6.26
Dividend Yield (Trailing)
0.64%
Dividend Yield (Forward)
0.66%
Total Yield
1.83%

Company Profile

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab (consisting of consumables and services related to life science and applied tools), and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. and China representing the largest country concentrations.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Core
Total Number of Employees
18,100

Competitors

Valuation

Metric
A
DHR
TMO
Price/Earnings (Normalized)
26.3130.0727.00
Price/Book Value
6.773.544.81
Price/Sales
6.267.975.27
Price/Cash Flow
22.6027.6625.35
Price/Earnings
A
DHR
TMO

Financial Strength

Metric
A
DHR
TMO
Quick Ratio
1.801.181.27
Current Ratio
2.611.681.75
Interest Coverage
14.5617.584.94
Quick Ratio
A
DHR
TMO

Profitability

Metric
A
DHR
TMO
Return on Assets (Normalized)
14.99%5.68%8.68%
Return on Equity (Normalized)
28.63%9.47%18.83%
Return on Invested Capital (Normalized)
19.60%6.69%11.14%
Return on Assets
A
DHR
TMO
See how this stock stacks up to its competitors with Morningstar Investor

Diagnostics & Research Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
TMO
Thermo Fisher Scientific IncVzwsk$221.8 Bil
DHR
Danaher CorpLjjjzl$189.5 Bil
IDXX
IDEXX Laboratories IncMtdkv$47.4 Bil
IQV
IQVIA Holdings IncVpsdbbh$45.8 Bil
MTD
Mettler-Toledo International IncVpyqws$27.6 Bil
ICLR
Icon PLCLzwhny$27.3 Bil
ILMN
Illumina IncLvvkjz$21.9 Bil
WAT
Waters CorpYzsg$20.5 Bil
LH
Laboratory Corp of America HoldingsGxhddv$18.4 Bil

Sponsor Center